Drug Trial Radar · NCT01247675
A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Nov 2010
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth hormone product over a period of 4 weeks (4 weekly administrations versus 28 daily administrations) in adults with Growth Hormone Deficiency.
Conditions
- Adult Growth Hormone Deficiency
Interventions
ACP-001 (TransCon hGH)Drug
s.c., weekly injection
ACP-001 (TransCon hGH)Drug
s.c., weekly injection
ACP-001 (TransCon hGH)Drug
s.c., weekly injection
OmnitropeDrug
s.c., daily injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator)Time frame: Start of study treatment through Week 4
- Incidence of Treatment Emergent Anti-hGH Binding Antibody FormationTime frame: Start of study treatment through Day 42
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Aarhus University Hospital
Aarhus, Denmark
Charité University Hospital Berlin
Berlin, Germany
University Hospital Genova
Genova, Italy
Karolinska University Hospital
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.